ACURIAN CASE STUDY:

Predictable, reliable, and measureable results

Acurian Delivers 32% of US Patient Randomizations to an Asthma Program

Respiratory disease is a core therapeutic area for this sponsor. When it announced the start of its Phase III program for its compound as a potential treatment for severe uncontrolled asthma, the sponsor was facing a crowded field. There were four other products in Phase III and multiple products in Phase II. Because this class of drug was in a race to approval, keeping the program on track and filing a BLA as quickly as possible were paramount.

Sites faced significant enrollment challenges caused by a difficult protocol.

To qualify, patients must have had two or more exacerbations in the past year; a high dose of inhaled corticosteroids was required; the study duration was long; and the drug was an injectable form. As a result, enrollment faltered, and a significant delay was projected – a major delay that was unacceptable in such a tight race to market.

The clinical trial team needed a reliable solution to close the gap, so they hired Acurian to support two protocols across US sites.

Acurian delivered 32% (120) of all US randomizations, over the time of its engagement.

Contribution of US Patient Randomizations



(continued on other side)

Acurian accelerated enrollment by over seven months for both protocols.

By increasing sites' enrollment rates, Acurian shortened the enrollment timelines for protocols 1 and 2 by 6 months and 7.7 months, respectively.



Acurian was the most effective enrollment solution, as well as the most cost-effective solution.

Acurian cost $12.1 million less than waiting seven months or more for sites to find enough patients and $7.7 million less than adding 129 sites (for a total of 399), which would have been required to reach the same enrollment volume in the same period of time.*



*IMS CRO CostPro® analysis

Acurian
The Global Enrollment & Retention Specialist

WHEN YOU CAN'T AFFORD A DELAY IN PATIENT ENROLLMENT

Acurian, Inc. is the leading full-service provider of global patient enrollment and retention solutions for the life sciences industry. For the past 20 years, our unique patient-first approach has provided sponsors with enrollment certainty by delivering the patients they need, when and where they need them.

www.acurian.com
enrollment.certainty@acurian.com
212520178

United States
Horsham, Pennsylvania
215.323.9000

Europe
Cambridge, United Kingdom
+44 1223 374799